Cargando…
Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel(®): A Case Report
The CLARINET study (ClinicalTrials.gov: NCT00353496) showed that somatostatin analogs are able to stabilize tumor growth in patients with intestinal and pancreatic neuroendocrine tumors (NETs). Here, we present a case of NET originating from the pancreatic tail that was treated with lanreotide Autog...
Autores principales: | Lybaert, Willem, Van Hul, Erik, Woestenborghs, Heidi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224256/ https://www.ncbi.nlm.nih.gov/pubmed/25408662 http://dx.doi.org/10.1159/000368207 |
Ejemplares similares
-
The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma
por: Lybaert, Willem
Publicado: (2014) -
High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report
por: Van Fraeyenhove, Frank, et al.
Publicado: (2014) -
Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016) -
Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel
por: Zafra, Gema Marín, et al.
Publicado: (2016) -
Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
por: Van Fraeyenhove, F., et al.
Publicado: (2012)